

IMMUNOMEDICS INC
Form DEFA14A
January 30, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

Immunomedics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Title of each class of securities to which transaction applies:

(1)

Aggregate number of securities to which transaction applies:

(2)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(3)

Proposed maximum aggregate value of transaction:

(4)

Total fee paid:

(5)

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:

(1)

Form, Schedule or Registration Statement No.:

(2)

Filing Party:

(3)

Date Filed:

(4)

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 IMMUNOMEDICS, INC. Advanced Antibody - Based Therapeutics
Oncology Autoimmune Diseases January 2017 Setting the Record Straight: Immunomedics is Acting in the Best
Interests of All Stockholders to Maximize Near - Term Value

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 Important Additional Information / Forward Looking Statements
Important Additional Information Immunomedics, Inc. (the “Company”), its directors and certain of its executive
officers will be deemed to be participants in the solicitation of proxies from Company stockholders in connection
with the matters to be considered at the Company’s 2016 Annual Meeting. The Company has filed a definitive proxy
statement and form of WHITE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in
connection with any such solicitation of proxies from Company stockholders. COMPANY STOCKHOLDERS ARE
STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT AND THE SUPPLEMENT
FILED ON JANUARY 9, 2017 (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS), THE
ACCOMPANYING WHITE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS THAT THE
COMPANY FILES WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION. Information regarding the identity of participants, and their direct or indirect
interests, by security holdings or otherwise, is set forth in the proxy statement and other materials filed by the
Company with the SEC. Stockholders will be able to obtain the proxy statement, any amendments or supplements to
the proxy statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at
www.sec.gov. Copies will also be available at no charge at the Company’s website at www.immunomedics.com, by
writing to Immunomedics, Inc. at 300 The American Road, Morris Plains, New Jersey 07950, or by calling the
Company’s proxy solicitor, or by calling Dr. Chau Cheng, Senior Director, Investor Relations & Corporate Secretary,
(973) 605 - 8200, extension 123. Forward - Looking Statements This presentation, in addition to historical
information, may contain forward - looking statements made pursuant to the Private Securities Litigation Reform Act
of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated
patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out -
licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating
results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual
results could differ materially from those expressed or implied herein. Factors that could cause such differences
include, but are not limited to, the Company’s dependence on business collaborations or availability of required
financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products
and finance our operations, new product development (including clinical trials outcome and regulatory requirements/a
ctions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our
drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products,
and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in
the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and
the Company expressly disclaims any obligation, to update or alter any forward - looking statements, whether as a
result of new information, future events or otherwise. 2

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 Setting the Record Straight on venBio's Presentation Filed on January 26,
2017 • In response to venBio's presentation filed on January 26, 2017, which was filled with serious
mischaracterizations and inaccuracies, Immunomedics' new Board simply wants to correct the record and provide the
facts • At the Annual Meeting of Stockholders on February 16, Immunomedics stockholders will be asked to make a
decision that will dramatically affect the immediate future of the Company's ongoing robust strategic process,
imminent Phase 3 trial initiation and near - term BLA filing for IMMU - 132 • Immunomedics' new Board remains
focused on successfully completing the strategic process, maximizing value for stockholders and providing
stockholders with the information needed to make a decision when voting 3

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 4 Immunomedics' New Board Formed in Response to Stockholder
Requests and is Truly Independent • Immunomedics listened to its stockholders and understood the need for change •
The Board began its search for new directors in advance of the venBio nominations • New independent Directors Dr.
Geoffrey Cox, Robert Forrester and Bob Oliver were identified by an independent search firm • New independent
Director and Vice Chairman Jason Aryeh was highly recommended and sought after for his reputation for stockholder
advocacy . In the past, he has worked successfully with the other new Board members to create value for stockholders
Your Board accelerated the appointment of its four new directors and implemented a leadership succession plan after
listening to the requests of stockholders and determining that a reasonable settlement with venBio was not achievable

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 5 Right Process Underway, Being Overseen by a New Board with the Right Experience • Independent third - party experts have conducted a full commercial assessment of the U.S. and European market opportunities for IMMU - 132, as well as an independent audit of Phase 3 and commercial manufacturing facilities, processes, and other relevant manufacturing and regulatory areas – The Company has engaged an independent, ex - FDA consultant to audit facilities and manufacturing documents, all in preparation for the Biologics License Application (BLA) for accelerated FDA approval of IMMU - 132 in patients with metastatic triple - negative breast cancer (TNBC) – To validate clinical results, an independent third - party review is well underway, looking at pertinent radiological scan results in a blinded fashion, as per FDA requirements – The Company’s clinical investigators are confirming the patient results of IMMU - 132 in TNBC and urinary bladder cancer (UC) in several articles recently published, scheduled to publish or under review for publication in major cancer journals; these articles confirm the results provided to the Company’s stockholders – Immunomedics offered a non - disclosure agreement to venBio under which it would share its independent expert analysis and demonstrate the credibility of its process, which venBio refused • Immunomedics will — and must — accomplish its timeline to start the Phase 3 trial of IMMU - 132 and submit the BLA filing in mid - 2017 Independent Board members Dr. Geoffrey Cox , Brian Markison and Bob Oliver have experience assembling a drug application and/or manufacturing complex biologic therapeutics at commercial scale

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 6 Right Process Underway, Being Overseen by a New Board with the
 Right Experience • Dr . Geoffrey Cox has 30+ years of experience in senior management of biologics GMP
 manufacturing operations and deep experience supporting pharmaceutical development, commercial manufacturing
 and organizational infrastructure in a regulated environment – 13 years at Genzyme Corporation — EVP of worldwide
 manufacturing operations; responsible for establishing U.S. manufacturing capabilities, specifically for Ceredase and
 Cerezyme , which became a \$1.3BN product for Gauchers disease – As Chairman, President and CEO of GTC
 Biotherapeutics , helped Company become first in the world to develop and achieve EU and U.S. regulatory approval
 for a transgenically manufactured human therapeutic protein – Previously served as interim CEO and director of QLT
 while Company conducted a strategic process, culminating in the acquisition of Aegerion and formation of new
 company, Novelion Therapeutics • Robert Forrester is CEO and a director of Verastem , Inc., a late clinical - stage
 oncology biopharma company, with relevant experience from both private and public life sciences companies, as well
 as business development, M&A and financial expertise – Verastem is a biopharma company with a Phase 3 oncology
 drug, with the Phase 3 data due shortly and the goal of filing with the FDA this year • Bob Oliver is CEO of Otsuka
 America Pharmaceutical and over the past 6+ years, has managed its Oncology business, including the promotion of
 Sprycel ® in partnership with Bristol - Myers Squibb for the treatment of CML – Direct experience helping to
 commercialize a major drug – ABILIFY ® (aripiprazole), which grew to the #1 pharmaceutical in the U.S. – and led
 the transfer of the ABILIFY® (aripiprazole) commercial responsibilities from Bristol - Myers Squibb to Otsuka – As
 VP & Global Business Manager, Oncology at Wyeth Pharmaceuticals, led the global launch of Torisel ® for the
 treatment of renal cell carcinoma

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 • Ligand Pharmaceuticals, Inc . (NASDAQ: LGND): – At request of
 activist hedge fund Third Point LLC, Mr. Aryeh became an advisor engaged to lead Ligand's strategic process. He
 successfully completed the task in five weeks and for no remuneration – Mr . Aryeh was then elected to serve on and
 successfully reconstituted a new stockholder - focused Board, hired an exceptional CEO, and co - created an acutely
 cash - flow focused business model – Ligand then expeditiously distributed \$250M, or \$15.00/share adjusted for the
 Company's stock split, of cash tax - free to its stockholders, which venBio neglects to include in its fabricated
 performance claims – Ligand has evolved from a Company generating substantial losses into a massively profitable
 stock; Ligand was named Fortune's highest - earning growth stock over the past three years and the sixth - highest
 growth stock in any industry – During 2016, Ligand's valuation had increased ~17X over past ~7 years – During Mr.
 Aryeh's Board tenure, Ligand has added ~150 externally funded corporate partnerships with more than 90 different
 pharmaceutical partners, all while reducing expenses by more than 90% • Novelion Therapeutics Inc. (NASDAQ:
 NVLN) (TSX: NVLN): – NVLN 's stock performance since Mr. Aryeh's Chairmanship began on 12/2/16 is actually up
 4% (from \$9.00 to \$9.38). v enBio is being completely dishonest in claiming that NVLN has lost 50% of its value
 since Mr. Aryeh became Chairman – Furthermore , NVLN beat analysts' expectations in its only quarter during Mr.
 Aryeh's Chairmanship 7 Jason Aryeh : Proven Track Record of Creating Value & Advocating for Stockholders'
 Interests “Life After Loeb: Ligand Pharmaceuticals Prospers In Stripped - Down Mode” - Forbes, July 1, 2015 “#6
 Ligand Pharmaceuticals – ‘This biotech licensor’s two hit drugs – Krypolsis , used to treat blood cancer, and Promacta ,
 used to prevent bleeding episodes – injected big royalties last year .’” - Fortune, 100 Fastest Growing Companies 2016

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 213 227 255 • QLT Inc. (formerly NASDAQ: QLTI) (formerly TSX: QLT) : – Thirty -
 five days after Mr. Aryeh became Chairman, QLT implemented a strategic repositioning significantly lowering the
 company's cost structure, including reducing its employee base by 68%, amongst other shareholder - focused
 initiatives – Less than four months later, Mr. Aryeh sold QLT's competitively inferior AMD drug, Visudyne , for
 \$112.5 million plus milestones – Then Chairman Aryeh quickly helped return \$3.92/share in QLT's first of two tax -
 free distributions of capital to shareholders. That was the first tax - free distribution of capital ever allowed by
 Canadian tax authorities – Mr . Aryeh has orchestrated the only two tax - free distributions of capital ever permitted by
 Canada when QLT later returned an additional \$1.14/share to shareholders, in the form of cash and shares of Aralez
 Pharmaceuticals – QLT's stock closed out its existence on 11/29/16 at \$1.95/share. Thus $\$3.92 + \$1.14 + \$1.95 = \7.01
 is higher than the stock price of \$6.69 on May 22, 2012, when Mr. Aryeh became involved with QLT. Thus, venBio's
 claim that QLT lost 50% of its value during Mr. Aryeh's tenure is a complete misrepresentation as stocks decline
 proportionally to the amount of a capital distribution. Furthermore, the true economic value of returning cash tax - free
 is considerably higher than the taxable sale of stock or a regular taxable dividend. – Not included in Mr. Aryeh's /QLT's
 creation of shareholder value are two exceptional mergers that Mr. Aryeh led, both of which were trumped by
 interlopers ~one month before their expected closings. QLT, at no fault of its own, lost a merger deal with Auxilium
 Pharmaceuticals, which had valued QLT at over \$7/share, post its previously completed \$3.92 distribution (some QLT
 shareholders took advantage of the announced AUXL transaction and sold QLT above \$7, thus returning more than
 \$11/QLT share) – Mr . Aryeh also executed multiple other returns of capital to shareholders via stock buybacks – QLT
 was actually up, despite losing two incredible mergers to interlopers, Endo for Auxilium & Sun Pharma for Insite
 Vision, at 85% & 97% premiums, respectively – Mr . Aryeh ultimately helped merge QLT with Aegerion
 Pharmaceuticals, a commercial - stage orphan drug company trading for only ~1.6X revenues 8 Jason Aryeh : Proven
 Track Record of Creating Value & Advocating for Stockholders' Interests

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 Jason Aryeh : Proven Track Record of Creating Value & Advocating for
 Stockholders' Interests • Aralez Pharmaceuticals (NASDAQ: ARLZ): – Aralez is a new specialty pharmaceutical
 company (formed in 2016) led by a world - class CEO Adrian Adams – In its few quarters of its existence, ARLZ has
 consistently exceeded analysts' earnings estimates and has completed two universally praised product acquisitions •
 Derma Sciences, Inc . (NASDAQ: DSCI): – During an activist campaign led by Broadfin Capital , Mr. Aryeh was
 contracted as a consultant to maximize shareholder value – Mr . Aryeh expeditiously helped the Company make a very
 effective leadership change and recommended a review of strategic alternatives led by Greenhill & Co. that resulted in
 the acquisition of BioD , which created significant value for shareholders – With Mr. Aryeh's assistance, Derma was
 recently sold by Greenhill & Co. for a 40% one - day premium, and a 135 % premium to its low price after its lead
 development program failed (a program that began years before Mr. Aryeh's hiring) • Myrexix , Inc. (formerly
 NASDAQ: MYRX): – During an activist campaign, Mr. Aryeh was appointed to the Board to stop the Company's
 wasteful spending on inferior oncology development programs – With Director Robert Forrester's assistance, Mr.
 Aryeh expeditiously shut down all of Myrexix ' programs and then returned \$ 2.86/share of cash tax - free to
 shareholders. Again, venBio completely neglects to include Myrexix ' large capital distribution in its fictitious
 performance claims – Mr . Aryeh then championed the sale of the MYRX shell/listing for additional value, creating
 positive shareholder value during his tenure on the Myrexix Board 9

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 Jason Aryeh : Proven Track Record of Creating Value & Advocating for
 Stockholders' Interests • Nabi Biopharmaceuticals (formerly NASDAQ: NABI): – Mr . Aryeh was placed on the Board
 as two of 10 Directors via activism led by Third Point LLC – Mr . Aryeh forced Nabi's decision to partner NicVax with
 GlaxoSmithKline – Nabi then distributed \$ 1.11/share tax - free to shareholders, again not included in venBio's
 performance misrepresentation – Nabi subsequently sold its listing plus \$27 million of cash to Biota Pharmaceuticals
 for a significant premium, completing Mr. Aryeh's Board service on November 9, 2012. Again, as opposed to
 venBio's completely fabricated assertions, Mr. Aryeh had absolutely no involvement with Biota or Aviragen
 Therapeutics • The Cystic Fibrosis Foundation: – Mr . Aryeh is extremely proud and honored to have served on the CF
 Foundation's Therapeutics Board since 2011 – The CF Foundation is renowned for having created "venture
 philanthropy“, and is universally recognized as one of the world's best healthcare charities – Mr . Aryeh helped the CF
 Foundation turn its \$150M funding used to help Vertex Pharmaceuticals develop transformative CF medications, into
 a \$3.3B cash payment from Royalty Pharma 10 Mr. Aryeh is clearly the Director whom shareholders would want to
 lead any strategic process and corporate reorganization

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 11 New Board is Acutely Focused on Expeditiously Maximizing
 Stockholder Value INDEPENDENT DIRECTOR ROLE & RESPONSIBILITIES FOR IMMUNOMEDICS Jason
 Aryeh • Vice Chairman of the Board • Chair of the Transaction Committee of the Board , overseeing broad strategic
 process with outside financial and strategic advisor Greenhill & Co. • Has held a significant number of discussions
 with Immunomedics' investors and has heard what they want: 1) near - term focus on successfully concluding the
 strategic process; 2) executing a Phase 3 clinical trial for IMMU - 132; and 3) filing the BLA Dr. Geoffrey Cox •
 Taken lead on reviewing IMMU - 132's CMC plans and CMC audit , including reviewing recommendations from the
 Company's meetings with the FDA • Confident that the Company is taking the right actions • Believes venBio's
 assertions about Company's manufacturing plans are without merit — concept of running validation batches in sequence
 would likely cause a significant delay in BLA submission • Chairman of the Nominating and Governance Committee,
 which has initiated search for new CEO Robert Forrester • Current CEO and director of Verastem — biopharma company
 with Phase 3 oncology drug • Has real world perspective of Immunomedics' current state and appreciation of risks in
 disrupting and delaying clinical, regulatory and business development processes • Impressed with data and potential of
 IMMU - 132 • Believes Immunomedics' plan i n place is sound Brian Markison • Lead Independent Director • 20+ years
 of experience in developing oncology products in various leadership positions at Bristol - Myers Squibb • Served as
 CEO of several other pharmaceutical companies with significant executive leadership, R&D, M&A, manufacturing
 and sales experience in pharmaceutical and life sciences industries Bob Oliver • Current CEO of Otsuka America
 Pharmaceutical and has d irect experience helping to commercialize a major drug • Without the orderly change in
 management that the new Board is overseeing, IMMU - 132 program will be put at serious risk of delay while
 jeopardizing its expected commercialization • Confident that Company's management is taking right steps to
 commercialize IMMU - 132

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 12 IMMU - 132 Data is Solid and Since ASCO 2016, Patient Results
Continue to Improve • IMMU - 132 data in TNBC patients is solid – Phase 2 clinical data now up to 85 of 100
assessable patients needed for BLA filing to FDA – Clinical investigators are publishing their results in major cancer
journals – Data to date show 81% of patients had tumor shrinkage from baseline measurements – These results and those
for tumors other than TNBC were presented by independent clinical investigators at the Company's Investor R&D
Day on January 18, 2017 • TNBC presentation at ASCO 2016 included new data , and despite Company disputing the
decision, ASCO committee ruled some data was identical to prior presentation from April 2016 and breached embargo
rules • Immunomedics made two other presentations at ASCO 2016 on IMMU - 132 in SCLC and NSCLC indications
, which were also presented at the April 2016 meeting but were not considered as breaching the embargo rules • After
ASCO 2016, new TNBC data accepted and presented at peer - reviewed San Antonio Breast Cancer Symposium in
December 2016

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 13 Robust Pipeline, Strong Relationships and Solid Development
Program • Contrary to what venBio stated in its presentation: – Immunomedics has engaged in seven licensing deals and
received multiple grant awards from the National Institutes of Health (NIH) and U.S. Department of Defense (DOD)
supporting Company programs and product development – The Company has launched five Phase 3 clinical trials ,
including for Leuko - Scan®, CEA - Scan®, two for epratuzumab and clivatuzumab – Immunomedics ' relationship with
Bayer continues ; in fact, Bayer is testing epratuzumab in a clinical trial as a therapy for patients with lymphoma using
product manufactured by the Company and supplied to Bayer – Veltuzumab continues to generate out - licensing
interest , but to date has never been in a registration trial – Immunomedics has manufactured and continues to
manufacture all antibody products for Phase 1 - 3 clinical trials venBio overlooks Immunomedics' strong pipeline and
the important relationships the Company has formed over the years

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 Stockholder Support Evidenced by Increasing Value Upon Achieving
 Recent Milestones 14 Immunomedics ' stock has increased 116% since the announced hiring of Greenhill & Co. and
 24.7% since appointing a new Board 10/24/16 10/31/16 11/7/16 11/14/16 11/21/16 11/28/16 12/5/16 12/12/16
 12/19/16 12/26/16 1/2/17 1/9/17 1/16/17 1/23/17 1/30/17 \$2.00 \$2.50 \$3.00 \$3.50 \$4.00 \$4.50 \$5.00 1/9/17:
 Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 1/12/17: Immunomedics
 Mails Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation 1/18/17: R&D Day
 Highlights IMMU-132 and Strength of Pipeline 10/24/16: Immunomedics Announces Greenhill & Co. as
 Strategic Advisor 11/16/16: venBio Select Advisor Reports a 9% Stake in IMMU and Files Preliminary Proxy to Elect a New
 Board 11/14/16: Immunomedics Announces Clinical Update on IMMU-132 in TNBC to be Presented at
 San Antonio Breast Cancer Symposium 12/6/16: Immunomedics Announces New Antibody-Dryg Conjugate
 IMMU-140 at Annual Meeting of American Society of Hematology 12/12/16: Immunomedics Announces Updated Phase II
 Results of IMMU-32 in mTNBC, Which Were Presented in a Poster Presentation at the San Antonio Breast Cancer Symposium
 116.3% +

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 Immunomedics Stock Appreciation vs. Industry Peer Group & Biotech
 Index Small / Mid Cap Biotech Oncology Peers Peer 1 - YR Stock Return (Mean) (as of 1/27/17 close) Karyopharm
 (KPTI) 82.5% Seattle Genetics (SGEN) 73.7% Genmab (GEN) 57.8% AB Science (AB) 42.6% MacroGenics
 (MGNX) (5.6%) Merrimack (MACK) (48.0%) CTI Biopharma (CTIC) (59.1%) Celldex (CLDX) (60.0%)
 ImmunoGen (IMGN) (71.6%) Peer Group (excluding IMMU) 1.4% NBI NASDAQ Biotech Index 4.1% IMMU
 161.2% 15 Immunomedics' Stock Has Appreciated Significantly Over the Past Year

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 16 venBio's Plan is to Make a Plan In venBio's own words from Slides 28
and 30 of their presentation , their objectives are to: • " Understand key open items..." • " Evaluate strategic options to
advance '132 as rapidly as possible..." • " Evaluate and identify key talent to focus on IMMUNOMEDICS - 132" • " Evaluate key operating
processes – clinical, manufacturing, regulatory, commercial, etc." • " Audit and evaluate finances, budgets, & resource
allocation" • " Evaluate financing needs and options" How do venBio's " clear objectives " put Immunomedics' stockholders
closer to realizing the value of their investment in the near term? Immunomedics is already executing on a plan
overseen by a new independent Board; the time needed for venBio to develop a plan will cause dramatic and
unnecessary value destruction and delay

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 17 venBio's Other Misleading Assertions IMMUNOMEDICS
STATEMENTS VENBIO ASSERTIONS THE FACTS • " venBio's demands for representation and unilateral veto
rights are especially unreasonable relative to the size of its stake in the company." • " venBio rejected [. . .] alternative
proposals, stating that it will not back down from its full demands." "As IMMU's largest stockholder, our interests are
directly aligned with investors, which is why we are fighting for truly independent representation at the Board level,
as evidenced by the fact that three of our four nominees are independent of venBio " "We have negotiated in good faith,
and it was the company that unilaterally ended negotiations the night after soliciting our proposal for resolving this
situation called off the negotiations and appointed a new unqualified board" x venBio has declined any settlement
proposal that denies venBio and its principals the power to unilaterally block any business transaction that they do not
support • "In fact, our newly appointed Vice Chairman and future Chairman, Jason Aryeh , was initially sought out by
venBio as a potential candidate for the venBio slate of nominees." "We never asked Jason Aryeh to join our slate of
nominees. We DO NOT support Mr. Aryeh as a director or Chairman, and we view him as unqualified based on his
past track record and lack of understanding of an R&D - stage oncology biotech company" x venBio contacted Jason
Aryeh beginning on November 11 through text messages and phone calls, asking him to lead their proxy contest and
serve on their slate. After Mr. Aryeh rejected their proposal, venBio later told Immunomedics and Greenhill & Co.
that they were considering Mr. Aryeh and respected him highly. Believing it would please venBio , Immunomedics
then reached out to Mr. Aryeh directly to offer a Board seat • "We believe that, the venBio nominees, if elected, would
delay the progress of IMMU - 132 by up to two years..." "This claim is completely baseless and false, and any delay
would be the direct result of intentional steps taken by the current management team" x venBio has stated that they
want the immediate resignation of Dr. Goldenberg, and the immediate termination of Ms. Sullivan, who have been
vital to the continued advancement of IMMU - 132, including critical interactions with clinical investigators and
regulatory agencies, including the FDA and the EMA in Europe • "...they shockingly don't even want to allow any
stockholders besides them to have the right to vote on any strategic transaction." "This statement is designed to confuse
stockholders and belies a complete misunderstanding of how pharmaceutical partnership deals are forged " x venBio
insists on the unilateral right to block any transaction. To break a potential Board stalemate on a transaction,
Immunomedics proposed submitting a stalemate to a stockholder vote to attempt to resolve a standstill and reach a
settlement to avoid a proxy contest

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
 126 116 114 90 48 242 242 242 213 227 255 18 IMMU Stockholders Have a Clear Choice – Vote the WHITE Proxy
 Card x Imminent Phase 3 trial and clear path to accelerated approval of IMMU - 132 in TNBC patients x Broad
 strategic process led by independent directors with assistance of outside financial advisor, Greenhill & Co. Continued
 progress toward value creation x Seeking control without offering stockholders a control premium x Insists on
 unilateral veto right on significant transactions Risk and potential value destruction x No detailed plan or new ideas to
 improve upon the Company's publicly stated strategy x Your new Board is committed to doing right by all
 stockholders Immunomedics x No concern about disrupting the Company's strategy at a critical juncture with
 significant opportunity for near - term value creation and expected accelerated approval of IMMU - 132 x Committed
 to best practices for corporate governance for stockholder democracy x Refuses to engage in any reasonable
 settlement x Your new Board and financial advisor have orchestrated and overseen a significant number of successful
 M&A transactions venBio

0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131
126 116 114 90 48 242 242 242 213 227 255 VOTE THE WHITE PROXY CARD TODAY Vote FOR all the
Immunomedics director nominees If you have already voted for venBio on a gold proxy card, it is not too late to
change your vote by using the WHITE proxy card to vote for ALL of your Immunomedics director nominees

– only your latest vote counts! 19